, is a radiofluorinated analog of the FDA-approved drug for multiple sclerosis 4-aminopyridine (4AP). This compound is currently under investigation as a PET tracer for demyelination. We recently described a novel chemical reaction to produce metafluorinated pyridines consisting of direct fluorination of a pyridine N-oxide and the utilization of this reaction for the radiochemical synthesis of [ 18 F]3F4AP. In this article, we demonstrate how to produce this tracer using an automated synthesizer and an in-house made flow hydrogenation reactor. We also show the standard quality control procedures performed before releasing the radiotracer for preclinical animal imaging studies. This semi-automated procedure may serve as the basis for future production of [ 
Introduction
The ability to trace a small-molecule drug non-invasively within the human body has great potential towards precision medicine. Among molecular imaging techniques, positron emission tomography (PET) has many favorable characteristics: the high sensitivity of PET detectors allows detection and quantification of very small amounts of radioactive material and the characteristics of the scanners allow accurate spatial mapping of the drug localization 1, 2, 3 . For example, PET allows detection and localization of tumors and metastasis based on the level of uptake of a radioactive glucose analog, [ 18 F]FDG 4 . PET can also provide localization and quantification of specific brain receptors and their occupancy which can be valuable for diagnosing and understanding neurological and psychiatric disorders 5 . In order to develop a small molecule PET tracer, the compound of interest must be labeled with a positron-emitting isotope, typically 11 C or 18 F. Between these two radioisotopes, 18 F has a longer half-life (109 min vs. 20.3 for 11 C), which allows multi-dose and offsite production. Nevertheless, adding 18 F to a molecule can be challenging. 18 F labeling requires fast reactions compatible with automation relieving the chemist of direct handling of the activity and receiving high-absorbed radiation doses.
We recently described the use of pyridine N-oxides as precursors for the fluorination of pyridines and the use of this chemistry in the radiochemical synthesis of [ 18 F]3F4AP 6 , a radiofluorinated analog of the FDA-approved drug for multiple sclerosis, 4-aminopyridine (4AP) 7, 8, 9 . This novel radiotracer is currently under investigation as a PET tracer for demyelination 10, 11, 12 . In this video article, we demonstrate the semiautomated synthesis of this compound using an IBA Synthera Synthesis Unit (henceforth referred to as "the synthesizer") and an in-house made flow hydrogenation device. The synthesis is based on the reaction shown in Figure 1 . Preparation for the procedure takes approximately 1 h, radiolabeling and purification 1.5 h and quality control procedures 0.5 h.
Protocol
CAUTION: All procedures involving the use of radioactive materials must be approved by the local Office of Radiation Safety. When working with radioactive materials wear a lab coat and personal radiation badges. Use two layers of gloves at all times and check hands with a Geiger counter after each step that involves handling radioactivity. If the gloves are contaminated with radioactivity discard and replace outer gloves. Use appropriate shielding, minimize time in contact with the radiation source and maximize distance. 2. When the radioactive peak appears on the HPLC software toggle the collection valve to collect the product. Measure radioactivity of crude product using a dose calibrator. NOTE: The crude product should be injected into an automated HPLC system inside a hot cell. After purification, the final product is then collected and dispensed into an aseptic ISO class 5 laminar air flow hot cell as per USP and FDA regulations.
Day of Experiment: Purification and Preparation of the Dose
1. Inject crude product into the HPLC and use the automated fraction collector to collect the fractions corresponding to the final product peak. Each tube contains 0.66 mL of solution. NOTE: HPLC conditions: XDB 5 µm, 9.4 x 250 mm C18 column. Flow 4 mL/min. Mobile phase (50 mM Na 2 HPO 4 , 10 mM TEA, 5% EtOH). Isocratic 15 min. Collect 4-15 min. 2. Measure the radioactivity of each fraction using a dose calibrator and record it. Combine the fractions with highest amounts of radioactivity (typically tubes 14-18). 3. Draw the product solution with a 10 mL syringe and pass the sample through 0.22 µm filter into a sterile vial. Record the amount of radioactivity, end of synthesis time and solution volume on the vial label. This is the final dose for injection. Put aside ~0.8 mL of the solution for quality control tests.
Day of Experiment: Quality Control (QC) Tests

Before dose release:
Inspect the dose through lead-shielded glass. The solution must be clear, colorless and free of particulate matter. 2. Radiochemical identity:
1. For RadioTLC: spot a drop of the sample on a TLC plate side-by-side with the reference standard. Run TLC plate on a TLC chamber using 95% MeOH: 5% acetic acid. Visualize the reference standard under UV illumination and mark its position with pencil. 2. Tape the TLC plate to the stage of the radioTLC scanner and record time of the peak. R f values of the reference standard and radioactive peak must match within 5%. 3. For RadioHPLC: run 10 µL of the dose with and without the reference standard on the HPLC. Retention time of the reference standard and the radioactive peak must match. A single coelution peak must be seen on the spiked sample.
3. For radiochemical purity: measure the area under curve for the radioHPLC and radioTLC target peaks. The area of the target peak must be >95% of the area for all radioactive peaks combined. 4. For the specific radioactivity: calculate the specific radioactivity as the amount of radioactivity in the peak (measured on step 5.2) over the mass amount determined from the area under the curve of the UV HPLC trace using a pre-established calibration curve. The specific radioactivity must be higher than 50 mCi/µmol. 5. For the residual solvent analysis: measure the amount of residual solvents (MeCN, MeOH) in the dose using gas chromatography. Solvents levels must be < 0.04% for acetonitrile and <3,000 ppm for methanol. The amount of EtOH must be less than 10% w/v. 6. For the sterile filter integrity test (bubble point): connect the filter used in step 5.3 to a nitrogen supply equipped with a pressure regulator and submerge the needle in water. Gradually open the gas valve while watching the pressure gauge. The filter should withstand pressures up to 50 psi without bursting as evidenced by the lack of a stream of bubbles from the needle. Increase the pressure beyond 50 psi until a stream of bubbles comes out of the needle. Record this pressure, it is the burst pressure and it must be >50 psi. 7. For the radionuclide half-life: measure the radioactivity of the product at two time points ≥10 min apart in a dose calibrator. Calculate the halflife using the equation below. The half-life must match that of where t is the interval between measurements and A 1 , A 2 the activity measured at each time point. 8. For the radionuclidic identity and purity: obtain the γ-ray spectrum of a sample of the product using a gamma counter. The spectrum should exhibit one single photo-peak at an energy of 511 keV. There should be no other photo-peaks in the spectrum. 9. For the endotoxin analysis: measure the endotoxin levels using a LAL chromogenic endotoxin quantitation test. Endotoxin levels must be <1.75 EU/mL for a 1:10 diluted product with a final product volume of 10 mL. 10. Document the results from each QC test. Release the dose for animal studies only if all the tests passed. 11. Post-dose release:
For the sterility test: add a sample of the dose to both fluid thioglycolate and trypticase soy broth. No growth must be seen on the media after 14 days. (Table 1) 1. For the non-decay corrected radiochemical yield (n.d.c. RCY): calculate the n.d.c. RCY as the amount of radioactivity in the final product over the starting radioactivity. 2. For the radiolabeling efficiency: calculate the labeling yield as the ratio of radioactivity in the collection vial over radioactivity in the alumina-N cartridge (unincorporated [ 3. For the hydrogenation yield: calculate the hydrogenation yield as the amount of radioactivity in the desired peak over the radioactivity injected into the HPLC. 4. For the filtering losses: calculate filtering loses as the radioactivity remaining in the filter and syringe over radioactivity before filtering.
Day of Experiment: Calculations
Representative Results
The radiochemical synthesis of [ 18 F]3F4AP comprises two steps (Figure 1) . The first step is carried out in a fully automated fashion using the synthesis unit (Figure 3) . This cassette-based system uses four reagent vials and one reactor vial and has computer-controlled valves that allow transfer and mixing of reagents as well as heating, pressurizing and evacuating the reactor. In addition, it supports standard solidphase extraction cartridges for separation of reagents. The computer interface allows users to write and modify scripts in order to run their own syntheses. In the case of [ 18 F]3F4AP, the synthesis procedure is comprised of five basic parts. In the first part, the synthesizer performs selfcheck steps, preheats the reactor and waits for operator's signal that the 18 F is ready. During the second part, the [ 18 F]fluoride is transferred from the 18 F vial into the anion exchange cartridge and eluted from the cartridge into the reactor using a solution tetrabutyl ammonium bicarbonate. The third part, the synthesizer azeotropically dries the [ 18 F]fluoride under vacuum to make it reactive towards nucleophilic displacement. In the fourth part, the precursor is automatically added to the reactor where it reacts with the 18 F -to generate the labeled compound. Finally, the reaction is quenched by the addition of 0.2% oxalic acid in methanol, which prevents base-promoted decomposition of the product, and the final solution is pressure-transferred to the collection vial after passing through an alumina-N cartridge that traps any unreacted fluoride.
After the labeling step is completed a small sample can be taken for quality control. Running a sample on the HPLC provides confirmation that the labeling step worked and an estimation of the radiochemical purity (Figure 4) . Also, from the UV trace on the HPLC the mass amount of product can be calculated using a pre-established calibration curve.
While the in-process quality control HPLC is running, the second reaction step, reduction of the N-oxide and nitro groups, is performed. In order to do this, the labeled product is automatedly injected into an in-house hydrogenation device based on the method published by Yoswathananont et al. 13 ( Figure 2 ). This device consists of an HPLC pump and a compressed hydrogen tank connected to the flow hydrogenation device through lines equipped with check valves to prevent back-streaming. The product is pushed by the HPLC pump and mixed with hydrogen in a T-shaped mixer. This mixture is then passed through a small cartridge containing 10% Pd/C catalyst on a solid support. After passing through the catalyst the reduced product is then collected in small fractions.
Following hydrogenation, the crude product is transported and manually injected into the HPLC for purification of the final product ( Figure 5) . The mobile phase of the HPLC has been selected to be compatible with animal injection. The peaks corresponding to the product are then collected and filtered-sterilized to obtain the final dose.
Prior to releasing the dose for PET imaging studies, quality control tests are performed. These tests are performed to ensure that the tracer is the chemical entity that it is supposed to be and that it is safe for injection. Some of these tests may not be required for injection into animals but it is generally recommended to follow the human use guidelines. Doing so ensures quality of the product, which increases confidence in the results and greatly facilitates future transition to manufacturing the product for human injection. Table 1 contains the typical synthesis parameters including initial amount radioactivity, initial amount of precursor, yield for each step, specific activity, filtering loses, etc. These parameters are useful troubleshooting occasional failures and future optimization of the procedure. · There are leaks on the TBA-HCO 3 vial. Make sure the crimp seal is tight and the septum is not pierced prior to installing it on the IFP. Additional peaks on radioHPLC · Nitro group is being substituted: reduce the reaction temperature or shorten reaction time.
· Catalyst is not good. Use a new cartridge.
· Flow is too fast and does not allow sufficient contact between catalyst and substrate. Decrease flow.
Hydrogenation reaction does not work · Hydrogen pressure is too low. Increase H 2 pressure.
Hydrogen pressure increases dramatically during procedure · Cartridge integrity is compromised and solid support is clogging the lines. Stop the flow and shut off the gas. Let radioactivity decay.
Remove catalyst cartridge and flush the system. Put a new cartridge.
Hydrogenation yield is low · Too many impurities competing for the catalyst (MeCN, oxalic acid). Decrease amount of impurities or increase mass of precursor (Warning: increasing precursor amount will reduce specific activity).
· There is a leak in the system. Check for leaks and backflush into the hydrogen line.
Recovery of radioactivity from hydrogenation step is low · pH of the mobile phase is low. Make sure that the pH ≥ 8.
The final product peak on the HPLC looks broad · Column is not in good condition. Replace column. Use column compatible with basic pH. 
Discussion
The preparation of PET tracers requires efficient labeling with minimal user intervention to minimize radiation exposure 14 . Here, we described the first semi-automated procedure for the radiochemical synthesis of [ 18 F]3F4AP, a PET tracer currently under investigation for imaging demyelination. This semi-automated method produces the radiotracer with high purity and sufficient specific activity for animal studies. Prior methods for the synthesis of this compound relied on manual synthesis 6 , which significantly limits the amount of radioactive tracer that can be produced. Having an automated method for the synthesis also provides more reproducible yields and makes it easier to transfer the procedure to other laboratories with similar equipment. Future efforts to fully automate the procedure will be instrumental to the production of the tracer in high amounts for studies in large animals or humans.
This procedure uses nucleophilic exchange of 19 F for 18 F to incorporate the radioisotope into the molecule of interest. The advantages of this reaction are that it is fast and produces almost exclusively the desired product without the need to perform a potentially lengthy purification step to remove excess of precursor. One limitation of using fluoride-exchange labeling reactions such as the one used here is that due to initial mass of cold compound the final specific activity defined as amount of radioactivity in mCi over amount of compound in µmol may be limited. Under our standard conditions, starting with 100-200 mCi of with high specific activity (1-3 Ci/µmol) by starting with high activity and low precursor amounts 15, 16 .
As with all radiochemical syntheses of PET tracers, it is critical to work quickly in order to minimize radioactive decay. It is also important to minimize the time handling the radioactive materials, use proper shielding and maximize the distance between the radioactive material and the user to minimize radiation exposure. These aspects are particularly important during the second half of the protocol (purification and quality control) in which the user has to manually inject the solution into the HPLC, collect the fractions and filter the final product.
As with all radiochemical syntheses of PET tracers, it is critical to work quickly in order to minimize radioactive decay. It is also important to minimize the time handling the radioactive materials, use proper shielding and maximize the distance between the radioactive material and the user to minimize radiation exposure. These aspects are particularly important during the second half of the protocol (hydrogenation and purification) in which the user has to manually inject the solution into the hydrogenator, collect the fractions, set up the drying procedure, redissolve the product in buffer and filter it. During the filtering step it is easy to lose a large amount of radioactive material in the walls of the vials. Thus, it is important to try to collect all the liquid prior to filtering. Using a greater amount of buffer to dissolve may improve the yield of recovery but its use is discouraged because it will require injecting a larger volume on the HPLC, causing the peak to broaden and increase the volume of the final dose.
In order to troubleshoot and optimize the procedure is important to keep track of the yields of each step. For most steps this is done simply by measuring the amount of radioactivity before and after any step. In the case of the reaction the yields can be calculated through quantification of the HPLC peaks. Table 1 in the Results Section shows the typical yields for each step. Table 2 below lists many of the commonly encountered failures with potential reasons for the failure and how to correct them.
Finally, even though the procedure demonstrated here is specific for the synthesis of [
18 F]3F4AP, the general workflow and many of the individual steps are common to the synthesis of other compounds 17 .
In this article we also demonstrated the typical QC tests performed on any PET tracer.
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